ReviewCurrent neuropharmacology2019
Different Generations of Type-B Monoamine Oxidase Inhibitors in Parkinson's Disease: From Bench to Bedside.
Review in Current neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.
- Evaluation of the efficacy and cost-effectiveness of safinamide versus rasagiline: a systematic review.Journal of comparative effectiveness research · 2025Pooled it
- Effects of Safinamide on Motor and Non-Motor Symptoms in Patients with Parkinson's Disease and Motor Fluctuations.European neurology · 2024Pooled it
- Safety, Tolerability, and Pharmacokinetics of the Monoamine Oxidase B Inhibitor, HEC122505, and its Major Metabolite After Single- and Multiple- Ascending Dose, and Food Effect Study in Healthy Chinese Subjects.European journal of drug metabolism and pharmacokinetics · 2024Trial
- Consensus Molecules Associated with Parkinson's Disease.Neurology international · 2026Review
- Monoamine Oxidase Inhibitors in Drug Discovery Against Parkinson's Disease: An Update.Pharmaceuticals (Basel, Switzerland) · 2025Review
- The Role of MAO-B Inhibitors in Fatigue in Parkinson's Disease: A Narrative Review.Journal of clinical medicine · 2025Review
- Expression of amine oxidase-related proteins in breast phyllodes tumor.Histology and histopathology · 2025Article
- Parkinson's Disease: Unravelling the Medicinal Perspectives and Recent Developments of Heterocyclic Monoamine Oxidase-B Inhibitors.CNS & neurological disorders drug targets · 2025Review
- Monoamine Oxidase B in Cancers: Implications for Therapeutics and Prognosis.Journal of inflammation research · 2025Review
- Neuropharmacological Interventions of Plant Origin for Parkinson's Disease: A Comprehensive Appraisal.Current neuropharmacology · 2025Review
- Small Molecules in Parkinson's Disease Therapy: From Dopamine Pathways to New Emerging Targets.Pharmaceuticals (Basel, Switzerland) · 2024Review
- The Role of Fullerenes in Neurodegenerative Disorders.Journal of nanotheranostics · 2024Article
- Identification and Characterization of Neuroprotective Properties of Thaumatin-like Protein 1a fromNutrients · 2024Article
- Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease.Nature. Mental health · 2024Article
- Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings.Neural regeneration research · 2024Review
- Natural Products as Monoamine Oxidase Inhibitors: Potential Agents for Neurological Disorders.Combinatorial chemistry & high throughput screening · 2024Review
- Computational exploration of acefylline derivatives as MAO-B inhibitors for Parkinson's disease: insights from molecular docking, DFT, ADMET, and molecular dynamics approaches.Frontiers in chemistry · 2024Article
- Orally Induced High Serum Level of Trimethylamine N-oxide Worsened Glial Reaction and Neuroinflammation on MPTP-Induced Acute Parkinson's Disease Model Mice.Molecular neurobiology · 2023Article
- Inhibition of Enzymes Involved in Neurodegenerative Disorders and AMolecules (Basel, Switzerland) · 2023Article
- An efficient method to access spiro pseudoindoxyl ketones: evaluation of indoxyl and theirRSC advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three inhibitors of type-B monoamine oxidase (MAOB), selegiline, rasagiline, and safinamide, are used for the treatment of Parkinson's disease (PD). All three drugs improve motor signs of PD, and are effective in reducing motor fluctuations in patients undergoing long-term L-DOPA treatment. The effect of MAOB inhibitors on non-motor symptoms is not uniform and may not be class-related. Selegiline and rasagiline are irreversible inhibitors forming a covalent bond within the active site of MAOB. In contrast, safinamide is a reversible MAOB inhibitor, and also inhibits voltage- sensitive sodium channels and glutamate release. Safinamide is the prototype of a new generation of multi-active MAOB inhibitors, which includes the antiepileptic drug, zonisamide. Inhibition of MAOB-mediated dopamine metabolism largely accounts for the antiparkinsonian effect of the three drugs. Dopamine metabolism by MAOB generates reactive oxygen species, which contribute to nigro-striatal degeneration. Among all antiparkinsonian agents, MAOB inhibitors are those with the greatest neuroprotective potential because of inhibition of dopamine metabolism, induction of neurotrophic factors, and, in the case of safinamide, inhibition of glutamate release. The recent development of new experimental animal models that more closely mimic the progressive neurodegeneration associated with PD will allow to test the hypothesis that MAOB inhibitors may slow the progression of PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.